References
- Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–6487.
- Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
- Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer. 2002;9(2):75–85.
- Genentech. Herceptin (trastuzumab) US Prescribing Information (November 2018). July 2022]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf.
- Roche. Herceptin (trastuzumab) EU Summary of Product Characteristics (September 2021). July 2022]; Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin.
- China National Medical Products Association. Injectable trastuzumab biosimilar principles for clinical trials. July 2020. Last accessed September 2022. https://www.nmpa.gov.cn/directory/web/nmpa/images/16LJ5NPDxrN19bptaWucn6zuA4MvG0qnB2bSyytTR6da4tbzUrdTyLnBkZg==.pdf.
- Blackwell K, Gligorov J, Jacobs I, et al. The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer. 2018;18(2):95–113.
- Martinez-Saez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17(10):594–604.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
- World Health Organization (WHO). Essential medicines list. 2022 July; Available from: https://list.essentialmeds.org/medicines/106.
- Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99–113.
- Zhang H, Deng M, Lin P, et al. Frontiers and opportunities: highlights of the 2nd annual conference of the Chinese antibody society. Antibody Therapeutics. 2018;1(2):27–36.
- Accord Healthcare. Zercepac (trastuzumab) EU summary of product characteristics (February 2022). July 2022; Available from: https://www.ema.europa.eu/en/documents/product-information/zercepac-epar-product-information_en.pdf
- Henlius. More flexible medication, 60mg specification Hanquyou® was officially approved for listing. July 2022; Available from: https://www.henlius.com/NewsDetails-3168-26.html.
- Xie L, Zhang E, Xu Y, et al. Demonstrating analytical similarity of trastuzumab biosimilar HLX02 to herceptin® with a panel of sensitive and orthogonal methods including a novel FcγRIIIa affinity chromatography technology. BioDrugs. 2020;34(3):363–379.
- Xu B, Zhang Q, Sun T, et al. Efficacy, Safety, and Immunogenicity of HLX02 compared with reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a randomized phase III equivalence trial. BioDrugs. 2021;35(3):337–350.
- Zhu X, Ding Y, Yu Y, et al. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Cancer Chemother Pharmacol. 2020;87(3):349–359.
- U.S. Food and Drug Administration Center for Drug Evaluation and Research (2001) Guidance for Industry: statistical approaches to establishing bioequivalence. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence. Accessed 2022 Mar 07.
- Wynne C, Harvey V, Schwabe C, et al. Comparison of subcutaneous and intravenous administration of trastuzumab: a Phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol. 2013;53(2):192–201.
- Leyland-Jones B, Gelmon K, Ayoub J-P, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003;21(21):3965–3971.
- European Medicines Agency (2019) Guideline on the investigation of bioequivalence. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 2022 Mar 07.
- Pivot X, Curtit E, Lee YJ, et al. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects. Clin Ther. 2016;38(7):1665–1673.e3.
- Esteva FJ, Stebbing J, Wood-Horrall RN, et al. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother Pharmacol. 2018;81(3):505–514.
- Waller CF, Vutikullird A, Lawrence TE, et al. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401Ovs. EU-trastuzumab and US-trastuzumab. EU-trastuzumab and US-trastuzumab. Br J Clin Pharmacol. 2018;84(10):2336–2343.
- Hanes V, Chow V, Zhang N, et al. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol. 2017;79(5):881–888.
- Yin D, Barker KB, Li R, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). Br J Clin Pharmacol. 2014;78(6):1281–1290.